DE102010015788A1 - Use of honokiol and magnolol or Magnolia bark extract containing honokiol and magnolol, for the preparation of topical formulation to increase microcirculation of skin and/or angiogenic effect of topical preparation - Google Patents
Use of honokiol and magnolol or Magnolia bark extract containing honokiol and magnolol, for the preparation of topical formulation to increase microcirculation of skin and/or angiogenic effect of topical preparation Download PDFInfo
- Publication number
- DE102010015788A1 DE102010015788A1 DE102010015788A DE102010015788A DE102010015788A1 DE 102010015788 A1 DE102010015788 A1 DE 102010015788A1 DE 102010015788 A DE102010015788 A DE 102010015788A DE 102010015788 A DE102010015788 A DE 102010015788A DE 102010015788 A1 DE102010015788 A1 DE 102010015788A1
- Authority
- DE
- Germany
- Prior art keywords
- magnolol
- honokiol
- preparation
- topical
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- VVOAZFWZEDHOOU-UHFFFAOYSA-N honokiol Natural products OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 241001673966 Magnolia officinalis Species 0.000 title claims abstract description 20
- 239000000284 extract Substances 0.000 title claims abstract description 19
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 title claims abstract description 16
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 230000004089 microcirculation Effects 0.000 title claims abstract description 8
- 230000000699 topical effect Effects 0.000 title claims abstract description 7
- 239000012049 topical pharmaceutical composition Substances 0.000 title abstract description 4
- 230000002491 angiogenic effect Effects 0.000 title abstract description 3
- 230000002500 effect on skin Effects 0.000 title abstract description 3
- 239000002537 cosmetic Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 240000003293 Magnolia grandiflora Species 0.000 claims description 2
- 235000008512 Magnolia grandiflora Nutrition 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims 2
- 210000003491 skin Anatomy 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 235000014676 Phragmites communis Nutrition 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- -1 tinctures Substances 0.000 description 5
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 229960005323 phenoxyethanol Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 4
- 229960003415 propylparaben Drugs 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 3
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 3
- 241000218378 Magnolia Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229940086555 cyclomethicone Drugs 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000218377 Magnoliaceae Species 0.000 description 2
- 244000062730 Melissa officinalis Species 0.000 description 2
- 235000010654 Melissa officinalis Nutrition 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 2
- 229960000601 octocrylene Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 229940000033 dermatological agent Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000004872 foam stabilizing agent Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
Abstract
Description
Die vorliegende Erfindung betrifft kosmetische Zubereitungen mit einem Gehalt an Magnolienrindenextrakt zur Steigerung der Mikrozirkulation der Haut sowie die Verwendung von Magnolienrindenextrakt zur Herstellung topischer Zubereitungen zur Steigerung der Mikrozirkulation der Haut.The present invention relates to cosmetic preparations containing magnolia bark extract for increasing the microcirculation of the skin and the use of magnolia bark extract for the preparation of topical preparations for increasing the microcirculation of the skin.
Das Blutgefäßsystem dient der Versorgung von Geweben mit Nährstoffen, Vitaminen, Sauerstoff, dem Transport von Hormonen von Sekretions- zu Zielorganen und der Entsorgung von metabolischen Endprodukten wie CO2 zum Ausscheidungsorgan Lunge oder Harnstoff zur Auscheidung via Niere.The blood vessel system is used to supply tissues with nutrients, vitamins, oxygen, the transport of hormones from secretion to target organs and the disposal of metabolic end products such as CO 2 to the excretory organ lung or urea for excretion via kidney.
Mit dem Begriff Mikrozirkulation bezeichnet man die Durchblutung und den Stoffaustausch in den kleinsten Blutgefäßen mit einer Größe kleiner als 100 μm (z. B. Kapillaren, Arteriolen, Venolen), den sogenannten Mikrogefäßen.The term microcirculation refers to the blood circulation and the mass transfer in the smallest blood vessels with a size smaller than 100 μm (eg capillaries, arterioles, venules), the so-called microvessels.
Die Mikrogefäße leiten das Blut und mit ihm lebensnotwendigen Sauerstoff und Nährstoffe zu jeder einzelnen Körperzelle und transportieren im Gegenzug Schlacken und Giftstoffe aus den Zellen ab. Im Kapillargebiet, der sogenannten Endstrombahn, fließt das Blut mit einer Geschwindigkeit von nur 1 cm in 20 s.The microvessels guide the blood and vital oxygen and nutrients to each cell of the body, and in turn, they remove waste products and toxins from the cells. In the capillary area, the so-called end stream, the blood flows at a rate of only 1 cm in 20 s.
Dies ist erforderlich, um den in der Endstrombahn vorgesehenen Austausch der Nähr- und Abfallstoffe (Stoffwechselendprodukte) möglich zu machen. Um dieses langsame Fließen des Blutes zu ermöglichen und konstant zu halten, können sich vor allem die arteriellen Blutgefäße maximal erweitern oder verengen.This is necessary in order to make possible the exchange of nutrients and waste (metabolic end products) intended in the final flow path. To allow for this slow flow of blood and keep constant, especially the arterial blood vessels can expand or narrow to a maximum.
Eines der wenigen Gewebe, die physiologischerweise nicht durchblutet sind, ist die Epidermis. Sie wird über die Mikrokapillaren der Dermis, die in einem in der Jugend regelmäßigen Muster von Papillen (Retezapfen) in die Epidermis vorstoßen, versorgt. Diese Architektur wurde mittels der klassischen Histologie – Biposieentnahme, Fixierung, Färbung und zahllose Schnitte – ermittelt und erkannt. Die quantitative histometrische Beschreibung wird durch prozessbedingte Schrumpfung der Gewebeproben erschwert bzw. verzerrt. Trotz allem erlaubte die klassische Technik, altersbedingte Degeneration der Mikrokapillarsysteme und Einebnung der Retezapfen, d. h. der Grenzzone Epidermis/Dermis zu erkennen. Dies zieht eine verminderte Ver- und Entsorgung der Epidermis nach sich (Verkleinerung der Transportfläche). Auch das Ausmaß der Verzahnungsfläche Epidermis/Dermis wird geringer, was zu einer verminderten mechanischen Festigkeit und Elastizität der Haut führt.One of the few tissues that are not physiologically perfused is the epidermis. It is supplied via the microcapillaries of the dermis, which penetrate into the epidermis in a pattern of papillae (reed cones) that is regular in the youth. This architecture was identified and identified using classical histology - biphosection, fixation, staining and countless cuts. The quantitative histometric description is complicated or distorted by process-related shrinkage of the tissue samples. Despite all this, the classical technique allowed age-related degeneration of the microcapillary systems and leveling of the reed cones, d. H. the epidermis / dermis border zone. This results in a reduced supply and disposal of the epidermis (reduction of the transport area). Also, the extent of the tooth surface epidermis / dermis is reduced, resulting in a reduced mechanical strength and elasticity of the skin.
Status und Veränderungen des Mikrokapillarsystems und des Retezapfenmusters lassen sich mittels moderner Techniken wie der konfokalen Mikroskopie in vivo – d. h. verletzungsfrei, beliebig oft wiederholbar und dynamisch auf aktuelle Einflüsse reagierend – an Probanden rasch (Minuten) darstellen, verfolgen und quantifizieren sowohl hinsichtlich der Dichte der Retezapfen bzw. Mikrokapillaren (Anzahl/Flächeneinheit) als auch in ihrer Höhe, was eine Abschätzung der Größe der Austauschfläche ermöglicht.Status and changes of the microcapillary system and the reed cone pattern can be determined by means of modern techniques such as confocal microscopy in vivo - d. H. injury-free, repeatable as often as desired and reacting dynamically to current influences - representing, tracking and quantifying rapidly (minutes) to test persons both in terms of the density of the reed cones or microcapillaries (number / area unit) and in their height, which is an estimate of the size of the exchange area allows.
Es war indes überraschend und für den Fachmann nicht vorherzusehen, daß die Verwendung von Honokiol und Magnolol oder Magnolienrindenextrakt mit einem wirksamen Gehalt an Honokiol und Magnolol zur Herstellung topischer Zubereitungen zur Steigerung der Mikrozirkulation der Haut und/oder angiogenetisch wirksamer topischer Zubereitungen den Nachteilen des Standes der Technik abhilft.However, it was surprising and unforeseeable for the skilled person that the use of honokiol and magnolol or magnolia bark extract with an effective content of honokiol and magnolol for the preparation of topical formulations for increasing the microcirculation of the skin and / or angiogenic topical formulations to the disadvantages of the prior art Technology helps.
Magnolien (Magnolia) sind eine Pflanzengattung in der Familie der Magnoliengewächse (Magnoliaceae). Diese enthält etwa 230 Arten, die aus Ostasien und Amerika stammen. Erfindungsgemäß kann der Magnolienrindenextrakt grundsätzlich allen Arten der Gattung Magnolia entnommen werden, wobei allerdings Magnolia grandiflora, und insbesondere Magnolia officinalis bevorzugt werden.Magnolia (Magnolia) is a genus of flowering plants in the magnolia family (Magnoliaceae). This contains about 230 species that come from East Asia and America. According to the invention, the magnolia bark extract can in principle be taken from all species of the genus Magnolia, although Magnolia grandiflora, and in particular Magnolia officinalis, are preferred.
Magnolien-Rinde wird in der Traditionellen Chinesischen Medizin (TCM) vor allem bei „Stagnation of qi” (low energy), emotionalem Stress, Entzündungen, innerer Unruhe und Angstzuständen eingesetzt.Magnolia bark is used in traditional Chinese medicine (TCM) mainly for "stagnation of qi" (low energy), emotional stress, inflammation, inner restlessness and anxiety.
Die Herstellung des verwendeten Extraktes erfolgt mit Hilfe von superkritischem CO2 oder Ethanol oder einer Ethanol/Wasser Mischung.The preparation of the extract used is carried out with the aid of supercritical CO 2 or ethanol or an ethanol / water mixture.
Als typische Inhaltstoffe und Leitsubstanzen Leitsubstanzen des Extraktes sind Magnolol und Honokiol definiert.Typical ingredients and lead substances of the extract are magnolol and honokiol.
Magnolol ist durch folgende Struktur gekennzeichnet: 
Honokiol ist durch folgende Struktur gekennzeichnet: 
Regelmäßige topische Anwendung von Magnolienrindenextrakt auf der Haut älterer Probanden führt zu reversibel und im Bereich jugendlicher Haut erhöhter Retezapfen- und Mikrokapillarendichte u. a. durch Stabilisierung und Degenerationsschutz bestehender Mikrokapiliaren. Diese strukturellen Veränderungen äußern sich sowohl in einer Verbesserung von Elastizitätsparametern der Haut (verlangsamte Bildung von Saugblasen) als auch des Feuchtigkeitsgehaltes und der Rauhigkeit der Hornschicht. Besonders ausgeprägt äußert sich diese juvenile Anatomie in der sie begleitenden optimierten Funktion bei der Antwort auf Stress (physikalischen Stress wie Kälte oder Trockenheit, agressive Agenzien wie Tenside, Stingings-Promotoren oder andere Irritantien, immunologisch in rascherer Abheilung von Dermatosen, Wundheilung oder bei mikrobiellem Befall usw.).Regular topical application of magnolia bark extract on the skin of elderly subjects leads to reversible and in the area of adolescent skin increased reed cone and Mikrokapillarendichte u. a. through stabilization and degeneration protection of existing microcapillaries. These structural changes are manifested both in an improvement in the elasticity parameters of the skin (slower formation of suction bubbles) and in the moisture content and roughness of the horny layer. This juvenile anatomy is particularly pronounced in the accompanying optimized response in response to stress (physical stress such as cold or dryness, aggressive agents such as surfactants, stinging promoters or other irritants, immunologically in faster healing of dermatoses, wound healing or microbial infestation etc.).
Die erfindungsgemäßen kosmetischen oder dermatologischen Zubereitungen können wie üblich zusammengesetzt sein und zur Behandlung, der Pflege und der Reinigung der Haut und/oder der Haare und als Schminkprodukt in der dekorativen Kosmetik dienen. Sie enthalten bevorzugt 0,001 Gew.-% bis 10 Gew.-%, bevorzugt 0,05 Gew.-% bis 5 Gew.-%, insbesondere 0,1–2,0 Gew.-%, bezogen auf das Gesamtgewicht der Zubereitungen, an Magnolienrindenextrakt.The cosmetic or dermatological preparations according to the invention may be composed as usual and used for the treatment, care and cleansing of the skin and / or the hair and as a make-up product in decorative cosmetics. They preferably contain 0.001% by weight to 10% by weight, preferably 0.05% by weight to 5% by weight, in particular 0.1-2.0% by weight, based on the total weight of the preparations, on magnolia bark extract.
Die erfindungsgemäß verwendeten Wirkstoffkombinationen lassen sich ohne Schwierigkeiten in gängige kosmetische oder dermatologische Formulierungen einarbeiten, vorteilhaft in Pumpsprays, Aerosolsprays, Cremes, Salben, Tinkturen, Lotionen, Nagelpflegeprodukte (z. B. Nagellacke, Nagellackentferner, Nagelbalsame) und dergleichen.The active compound combinations used according to the invention can be incorporated without difficulty into customary cosmetic or dermatological formulations, advantageously in pump sprays, aerosol sprays, creams, ointments, tinctures, lotions, nail care products (eg nail varnishes, nail polish removers, nail balms) and the like.
Es ist auch gegebenenfalls vorteilhaft, die Zusammensetzungen gemäß der Erfindung abzupuffern. Vorteilhaft ist ein pH-Bereich von 3,5–7,5. Besonders günstig ist es, den pH-Wert in einem Bereich von 4,0–6,5 zu wählen.It may also be advantageous to buffer the compositions according to the invention. A pH range of 3.5-7.5 is advantageous. It is particularly favorable to choose the pH in a range of 4.0-6.5.
Die kosmetischen und/oder dermatologischen Formulierungen gemäß der Erfindung können wie üblich zusammengesetzt sein und zur Behandlung der Haut und/oder der Haare im Sinne einer dermatologischen Behandlung oder einer Behandlung im Sinne der pflegenden Kosmetik dienen. Sie können aber auch in Schminkprodukten in der dekorativen Kosmetik eingesetzt werden.The cosmetic and / or dermatological formulations according to the invention may be composed as usual and used for the treatment of the skin and / or the hair in the sense of a dermatological treatment or a treatment in the sense of nourishing cosmetics. But they can also be used in make-up products in decorative cosmetics.
Zur Anwendung werden die kosmetischen und/oder dermatologischen Formulierungen gemäß der Erfindung in der für Kosmetika und Dermatika üblichen Weise auf die Haut und/oder die Haare in ausreichender Menge aufgebracht.For use, the cosmetic and / or dermatological formulations according to the invention are applied to the skin and / or the hair in a sufficient amount in the manner customary for cosmetics and dermatological agents.
Vorteilhaft sind solche kosmetischen und dermatologischen Zubereitungen, die in der Form eines Sonnenschutzmittels vorliegen. Vorteilhaft enthalten diese zusätzlich mindestens einen UVA-Filter und/oder mindestens einen UVB-Filter und/oder mindestens ein anorganisches Pigment.Advantageous are those cosmetic and dermatological preparations which are in the form of a sunscreen. Advantageously, these additionally contain at least one UVA filter and / or at least one UVB filter and / or at least one inorganic pigment.
Kosmetische Zubereitungen gemäß der Erfindung zum Schutze der Haut vor UV-Strahlen können in verschiedenen Formen vorliegen, wie sie z. B. üblicherweise für diesen Typ von Zubereitungen eingesetzt werden. So können sie z. B. eine Lösung, eine Emulsion vom Typ Wasser-in-Öl (W/O) oder vom Typ Öl-in-Wasser (O/W), oder eine multiple Emulsionen, beispielsweise vom Typ Wasser-in-Öl-in-Wasser (W/O/W), ein Gel, eine Hydrodispersion, einen festen Stift oder auch ein Aerosol darstellen. Cosmetic preparations according to the invention for the protection of the skin from UV rays can be in various forms, such as. B. are usually used for this type of preparations. So they can z. Example, a solution, a water-in-oil (W / O) or oil-in-water (O / W) type emulsion, or a multiple emulsions, such as water-in-oil-in-water type (W / O / W), a gel, a hydrodispersion, a solid stick or even an aerosol.
Die kosmetischen Zubereitungen gemäß der Erfindung können kosmetische Hilfsstoffe enthalten, wie sie üblicherweise in solchen Zubereitungen verwendet werden, z. B. Konservierungsmittel, Bakterizide, Antioxidantien, Parfüme, Mittel zum Verhindern des Schäumens, Farbstoffe, Pigmente, die eine färbende Wirkung haben, Verdikkungsmittel, oberflächenaktive Substanzen, Emulgatoren, weichmachende Substanzen, anfeuchtende und/oder feuchhaltende Substanzen, Fette, Öle, Wachse oder andere übliche Bestandteile einer kosmetischen Formulierung wie Alkohole, Polyole, Polymere, Schaumstabilisatoren, Elektrolyte, organische Lösungsmittel oder Silikonderivate.The cosmetic preparations according to the invention may contain cosmetic adjuvants, such as are commonly used in such preparations, for. Preservatives, bactericides, antioxidants, perfumes, foaming inhibitors, dyes, pigments having a coloring effect, thickeners, surfactants, emulsifiers, emollients, moisturizing and / or moisturizing substances, fats, oils, waxes or others customary constituents of a cosmetic formulation, such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
Emulsionen sind gemäß der Erfindung vorteilhaft und enthalten z. B. die genannten Fette, Öle, Wachse und anderen Fettkörper, sowie Wasser und einen Emulgator, wie er üblicherweise für einen solchen Typ der Formulierung verwendet wird.Emulsions are advantageous according to the invention and contain z. As mentioned fats, oils, waxes and other fatty substances, and water and an emulsifier, as it is commonly used for such a type of formulation.
Gele gemäß der Erfindung enthalten üblicherweise Alkohole niedriger C-Zahl, z. B. Ethanol, Isopropanol, 1,2-Propandiol, Glycerin und Wasser bzw. ein vorstehend genanntes Öl in Gegenwart eines Verdickungsmittels, das bei ölig-alkoholischen Gelen vorzugsweise Siliciumdioxid oder ein Aluminiumsilikat, bei wäßrig-alkoholischen oder alkoholischen Gelen vorzugweise ein Polyacrylat ist.Gels according to the invention usually contain lower C number alcohols, e.g. Example, ethanol, isopropanol, 1,2-propanediol, glycerol and water or an above-mentioned oil in the presence of a thickener which is preferably oily alcoholic gels preferably silica or an aluminosilicate, in aqueous-alcoholic or alcoholic gels preferably a polyacrylate.
Feste Stifte gemäß der Erfindung enthalten z. B. natürliche oder synthetische Wachse, Fettalkohole oder Fettsäureester. Bevorzugt werden Lippenpflegestifte sowie desodorierende Stifte (”Deo-Sticks”).Solid pins according to the invention contain z. As natural or synthetic waxes, fatty alcohols or fatty acid esters. Preference is given to lip balms and deodorant sticks ("deodorant sticks").
Als Treibmittel für erfindungsgemäße, aus Aerosolbehältern versprühbare kosmetische oder dermatologische Zubereitungen sind die üblichen bekannten leichtflüchtigen, verflüssigten Treibmittel, z. B. Kohlenwasserstoffe (Propan, Butan, Isobutan) geeignet, die allein oder in Mischung miteinander eingesetzt werden können. Auch Druckluft ist vorteilhaft zu verwenden.As propellants for inventive sprayable from aerosol containers cosmetic or dermatological preparations are the usual known volatile, liquefied propellant, z. As hydrocarbons (propane, butane, isobutane) suitable, which can be used alone or in mixture with each other. Also, compressed air is advantageous to use.
Vorteilhaft können die erfindungsgemäßen Zubereitungen zudem Substanzen enthalten, die UV-Strahlung im UVB-Bereich absorbieren, wobei die Gesamtmenge der Filtersubstanzen z. B. 0,1 Gew.-% bis 30 Gew.-%, vorzugsweise 0,5 bis 10 Gew.-%, insbesondere 1 bis 6 Gew.-% beträgt, bezogen auf das Gesamtgewicht der Zubereitung, um kosmetische Zubereitungen zur Verfügung zu stellen, die die Haut vor dem gesamten Bereich der ultravioletten Strahlung schützen.Advantageously, the preparations of the invention may also contain substances that absorb UV radiation in the UVB range, wherein the total amount of the filter substances z. B. 0.1 wt .-% to 30 wt .-%, preferably 0.5 to 10 wt .-%, in particular 1 to 6 wt .-%, based on the total weight of the preparation, to cosmetic preparations available which protect the skin from the entire range of ultraviolet radiation.
Bei kosmetischen Zubereitungen zur Pflege der Haare handelt es sich beispielsweise um Shampoonierungsmittel, Zubereitungen, die beim Spülen der Haare vor oder nach der Shampoonierung, vor oder nach der Dauerwellbehandlung, vor oder nach der Färbung oder Entfärbung der Haare angewendet werden, um Zubereitungen zum Fönen oder Einlegen der Haare, Zubereitungen zum Färben oder Entfärben, um eine Frisier- und Behandlungslotion, einen Haarlack oder um Dauerwellmittel.Cosmetic preparations for the care of the hair are, for example, shampooing agents, preparations which are used to rinse the hair before or after shampooing, before or after the permanent wave treatment, before or after dyeing or discoloring the hair, to make-up preparations or Inserting the hair, preparations for dyeing or decolorizing, a hairdressing and treatment lotion, a hair lacquer or permanent waving agent.
Die kosmetischen Zubereitungen enthalten Wirkstoffe und Hilfsstoffe, wie sie üblicherweise für diesen Typ von Zubereitungen zur Haarpflege und Haarbehandlung verwendet werden.The cosmetic preparations contain active ingredients and adjuvants such as are commonly used for this type of preparations for hair care and hair treatment.
Als Hilfsstoffe dienen Konservierungsmittel, oberflächenaktive Substanzen, Substanzen zum Verhindern des Schäumens, Emulgatoren, Verdickungsmittel, Fette, Öle, Wachse, organische Lösungsmittel, Bakterizide, Parfüme, Farbstoffe oder Pigmente, deren Aufgabe es ist, die Haare oder die Zubereitung selbst zu färben, Elektrolyte, Zubereitungen gegen das Fetten der Haare.As auxiliaries are preservatives, surface-active substances, substances for preventing foaming, emulsifiers, thickeners, fats, oils, waxes, organic solvents, bactericides, perfumes, dyes or pigments, whose job is to dye the hair or the preparation itself, electrolytes , Preparations against the greasing of the hair.
Kosmetische Zubereitungen, die ein Shampoonierungsmittel oder eine Wasch-, Dusch- oder Badezubereitung darstellen, enthalten vorzugsweise mindestens eine anionische, nicht-ionische oder amphotere oberflächenaktive Substanz oder Gemische daraus, mindestens eine dialkylsubstituierte Carbonsäure im wäßrigen Medium und Hilfsmittel, wie sie üblicherweise dafür verwendet werden.Cosmetic preparations which are a shampoo or a washing, showering or bathing preparation preferably comprise at least one anionic, nonionic or amphoteric surfactant or mixtures thereof, at least one dialkyl substituted carboxylic acid in the aqueous medium and adjuvants conventionally used therefor ,
Wirkungsnachweis effect detection
Verwendung von Honokiol/Magnolol aus Magnolienrindenextrakten zur Vorbeugung und Regeneration von Kapillarschädigungen der Haut wurde in einem 3-dimensionalen Angiogenese-Test mit humanen Hautendothelzellen und glatten Muskelzellen nachgewiesen.Use of honokiol / magnolol from magnolia bark extracts to prevent and regenerate capillary damage to the skin was demonstrated in a 3-dimensional angiogenesis test with human skin endothelial cells and smooth muscle cells.
Honokiol/Magnolol zeigten überraschend eine stabilisierende Wirkung nach entzündlicher Stressung der Kokulturspheroide auf. Die Ablösung und somit die Desintegration der Spheroide konnte um mehr als 13% vermindert werden. Auch die Anhaftung von Granulozyten an ein aktiviertes Endothel wurde signifikant vermindert. Beide Eigenschaften tragen somit zu einer gesteigerten Kapillarintegrität durch Honokiol/Magnolol bei. Die mikrokapillaren Gefäße werden somit vor stress- oder alterbedingter Degeneration geschützt. Das Kapillarsystem bleibt funktionell und strukturell in Takt, was einen direkten positiven Effekt auf die dermale Mikrozirkulation bedingt.Honokiol / Magnolol surprisingly showed a stabilizing effect after inflammatory stress on coculture pheroids. The detachment and thus the disintegration of the spheroids could be reduced by more than 13%. Also, the attachment of granulocytes to an activated endothelium was significantly reduced. Both properties thus contribute to an increased capillary integrity by honokiol / magnolol. The microcapillary vessels are thus protected from stress or age-related degeneration. The capillary system remains functionally and structurally in tact, which has a direct positive effect on the dermal microcirculation.
Die folgenden Beispiele sollen die Verkörperungen der vorliegenden Erfindungen verdeutlichen. Die Angaben beziehen sich stets auf Gewichts-%, sofern nicht andere Angaben gemacht werden. Rezepturbeispiele:
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010015788A DE102010015788A1 (en) | 2010-04-20 | 2010-04-20 | Use of honokiol and magnolol or Magnolia bark extract containing honokiol and magnolol, for the preparation of topical formulation to increase microcirculation of skin and/or angiogenic effect of topical preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010015788A DE102010015788A1 (en) | 2010-04-20 | 2010-04-20 | Use of honokiol and magnolol or Magnolia bark extract containing honokiol and magnolol, for the preparation of topical formulation to increase microcirculation of skin and/or angiogenic effect of topical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE102010015788A1 true DE102010015788A1 (en) | 2011-10-20 |
Family
ID=44730715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102010015788A Withdrawn DE102010015788A1 (en) | 2010-04-20 | 2010-04-20 | Use of honokiol and magnolol or Magnolia bark extract containing honokiol and magnolol, for the preparation of topical formulation to increase microcirculation of skin and/or angiogenic effect of topical preparation |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE102010015788A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150164780A1 (en) * | 2012-07-06 | 2015-06-18 | Beiersdorf Ag | Active ingredient combinations of magnolia bark extract and hyaluronic acid and the cosmetic and/or dermatological use thereof |
| CN105111050A (en) * | 2015-08-17 | 2015-12-02 | 重庆大学 | Method for continuously preparing highly pure magnolol and honokiol |
| US12311044B2 (en) | 2018-12-18 | 2025-05-27 | Conopco, Inc. | Antimicrobial composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60121155T2 (en) * | 2000-05-10 | 2007-06-06 | Colgate-Palmolive Co. | SYNERGISTIC ORAL COMPOSITION AGAINST DENTAL AND GINGIVITIS |
| DE102007028508A1 (en) * | 2007-06-18 | 2008-04-03 | Henkel Kgaa | Cosmetic/dermatological deodorant- or anti-transpirant composition comprises a deodorant- or anti-transpirant agent, antioxidant, complex binder, aromatic material and water in a carrier, where the composition is free of e.g. gallic acid |
| FR2939669A1 (en) * | 2008-12-17 | 2010-06-18 | Oreal | COSMETIC METHOD FOR CONTROLLING SKIN BLIND INDUCED BY UV RADIATION; Compositions. |
-
2010
- 2010-04-20 DE DE102010015788A patent/DE102010015788A1/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60121155T2 (en) * | 2000-05-10 | 2007-06-06 | Colgate-Palmolive Co. | SYNERGISTIC ORAL COMPOSITION AGAINST DENTAL AND GINGIVITIS |
| DE102007028508A1 (en) * | 2007-06-18 | 2008-04-03 | Henkel Kgaa | Cosmetic/dermatological deodorant- or anti-transpirant composition comprises a deodorant- or anti-transpirant agent, antioxidant, complex binder, aromatic material and water in a carrier, where the composition is free of e.g. gallic acid |
| FR2939669A1 (en) * | 2008-12-17 | 2010-06-18 | Oreal | COSMETIC METHOD FOR CONTROLLING SKIN BLIND INDUCED BY UV RADIATION; Compositions. |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150164780A1 (en) * | 2012-07-06 | 2015-06-18 | Beiersdorf Ag | Active ingredient combinations of magnolia bark extract and hyaluronic acid and the cosmetic and/or dermatological use thereof |
| US9402801B2 (en) * | 2012-07-06 | 2016-08-02 | Beiersdorf Ag | Active ingredient combinations of magnolia bark extract and hyaluronic acid and the cosmetic and/or dermatological use thereof |
| CN105111050A (en) * | 2015-08-17 | 2015-12-02 | 重庆大学 | Method for continuously preparing highly pure magnolol and honokiol |
| US12311044B2 (en) | 2018-12-18 | 2025-05-27 | Conopco, Inc. | Antimicrobial composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6766047B2 (en) | Γ-diketone for the treatment and prevention of aging skin and wrinkles | |
| EP1406599B1 (en) | Cosmetic and dermatological preparations containing creatine for treating and actively preventing dry skin and other negative alterations of the physiological homeostasis of healthy skin | |
| DE102013204088A1 (en) | Active ingredient combinations of alkylamidothiazoles and one or more cosmetically or dermatologically relevant fragrances | |
| WO2002000185A1 (en) | Use of calcium-releasing or binding substances for the specific attenuation or strengthening of the barrier function of the skin | |
| WO2011131439A1 (en) | Cosmetic or dermatological preparations comprising combinations of magnolia bark extract and alkyl sulphates | |
| WO2018137854A1 (en) | Active ingredient combinations consisting of trans-4-t-butylcyclohexanol and one or more alkylamidothiazoles as well as cosmetic or dermatological preparations containing said active ingredient combinations | |
| US11918666B2 (en) | Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment | |
| EP1172084A2 (en) | Cosmetic and dermatologic composition to eliminate sebum | |
| EP2560734B1 (en) | Cosmetic or dermatological preparations containing combinations of magnolia bark extract and acyl glutamates | |
| EP3122315B1 (en) | Active-ingredient combinations consisting of 4-hydroxyacetophenone and one or more glycerin and/or oligoglycerin esters of branched chains and/or unbranched chains of alkane carboxylic acids, and cosmetic or dermatological preparations containing said active-ingredient combinations | |
| DE102013200819A1 (en) | Active substance combination useful in a cosmetic- or dermatological formulation, comprises dehydroacetic acid and at least one polyol | |
| DE102004012135A1 (en) | Preparation against reddened skin | |
| DE102010015788A1 (en) | Use of honokiol and magnolol or Magnolia bark extract containing honokiol and magnolol, for the preparation of topical formulation to increase microcirculation of skin and/or angiogenic effect of topical preparation | |
| DE10352367A1 (en) | Treatment of rosacea using licochalcone A or extracts of Radix Glycyrrhizae inflatae, provides long-lasting suppression of redness and inhibits further outbreaks | |
| DE102014104257A1 (en) | Active ingredient combinations of ethylhexyl 2-cyano-3,3-diphenylacrylate and 4-hydroxyacetophenone and cosmetic or dermatological preparations containing these combinations of active ingredients | |
| WO2013189702A2 (en) | Cosmetic and dermatological preparation containing one or more substances which modulate the gene / protein for the endo180 receptor | |
| EP2560666B1 (en) | Agent combinationen of magnolia bark extract and surfactace active agents (polyglaceryl(3)-methylglucosedistearate) | |
| WO2018215218A1 (en) | Cosmetic or dermatological preparation containing a fish egg extract | |
| EP2589374B1 (en) | Use of magnolia bark extract for improved skin contouring or to counteract cellulite | |
| EP1834631B1 (en) | Cosmetic or dermatological preparations containing glycyrrhetin and/or glycyrrhizin and glucose derivatives or glycerin ethers | |
| JP2021522287A (en) | Topical use of at least one Umbelliferae seed oil to have a soothing effect on responsive skin | |
| DE202005002183U1 (en) | Skin-soothing cream lotion | |
| EP2086499B1 (en) | Cosmetic or dermatological preparations with a content of 2-isopropyl-5- methyl-cyclohexanecarbonyl-d-alanine methyl ester and one or more skin moisturising agents | |
| EP2589375A2 (en) | Use of magnolia bark extract to counteract skin aging | |
| DE19925551A1 (en) | Cosmetic and dermatological use of isopropylbenzyl salicylate against greasy skin, scalp and hair |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R012 | Request for examination validly filed | ||
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |